New Bill Could Waive Vaccine Maker Liability
On Dec. 19, the House approved a Republican-initiated list of liability protections for vaccine makers.
To make mass quantities of pandemic vaccines, drug companies say they need protection against lawsuits if the vaccines cause dangerous side effects. The waiver under debate offers injured victims little if any compensation in the event of a pandemic outbreak, except in the case of willful misconduct (as determined by the secretary of the Department of Health and Human Servies). This section can be waived in certain emergencies.
Meanwhile, House Democrats who oppose this waiver are putting together a counter-plan. They claim the unprecedented, broad waiver offers the public no protection and will make first responders and others hesitant to use pandemic vaccines. Democratic lawmakers such as Henry Waxman (D-CA) and Nita Lowey (D-NY) are proposing another plan that would provide a compensation plan and a means to sue the government in the event the vaccines cause harm.
The waiver is attached to a pending Department of Defense appropriations bill (Biodefense and Pandemic Vaccine and Drug Development Act of 2005) that could pass before the end of the year.
-Kaylynn Chiarello-Ebner
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Meeting Secondary Packaging Challenges of Innovative Delivery Systems for Biologics
February 6th 2025Rapid market growth in biologics is helping the packaging market expand as well, but the complex nature of biologics and the desire for personalized therapies present unique hurdles to make packaging solutions cost-effective and safe for patients.